

**REMARKS**

***Disposition of the Claims***

Upon entry of the amendments herein, Claims 1, 4-7, 16-17 and 25 are pending in the instant application. Claims 2-3, 8-15 and 18-24 have been cancelled.

Applicants have cancelled withdrawn method Claims 12-15.

No new matter has been added.

***Terminal Disclaimer***

Applicants have previously filed a terminal disclaimer over US Patent Applications Nos. 11/547,046 and 12/088,608 which was rejected. In a telephone conference with Examiner Stockton, she explained that although Applicants had change the corresponding address to customer number 75074, Applicants had not requested a change of the power of attorney to the new customer number. Since the attorney who signed the terminal disclaimer is on the new customer number but not on the original customer number, she is not authorized to file the terminal disclaimer.

Applicants filed a request for a change in power of attorney and a statement under 37 C.F.R. 3.73(b) on May 20, 2010, and Applicants are refiling the terminal disclaimers over US Patent Applications Nos. 11/547,046 and 12/088,608 herewith to address this rejection.

CONCLUSION

It is respectfully submitted that this application is in condition for allowance.

If there are any remaining issues or the Examiner believes that a telephone conference with the Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617)-871-7802.

Applicants believe that no additional fees are due with this filing. However, if any fees are required, the Commissioner is authorized to charge Deposit Account No. 50-4409 in the name of Novartis for any fees due.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
220 Massachusetts Ave. 232J  
Cambridge, MA 02139

  
\_\_\_\_\_  
Theresa A. Devlin  
Attorney for Applicant  
Reg. No. 45,361  
(617) 871-7802

Date: May 25, 2010